Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Cancer Type/Condition:  brain tumor
Stage/Subtype:  brain tumor
Trial Type:  Treatment
Treatment/Intervention:  vaccine therapy
Results 1-15 of 15 for your search:
Start Over
Study of a Drug [DCVax®-L] to Treat Newly Diagnosed GBM Brain Cancer
Phase: Phase III
Type: Treatment
Age: 18 to 65
Trial IDs: 020221, NCI-2010-00822, NCT00045968
Safety and Efficacy Study of SL-701, a Glioma-Associated Antigen Vaccine To Treat Recurrent Glioblastoma Multiforme
Phase: Phase II, Phase I
Type: Treatment
Age: 18 and over
Trial IDs: STML-701-0114, NCI-2014-01008, NCT02078648
ERC1671/GM-CSF/Cyclophosphamide for the Treatment of Glioblastoma Multiforme
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: ERC1671-H02, NCI-2014-00737, 2013-9863, ERC1671, UCI 13-14, NCT01903330
Vaccine therapy in Treating Patients with Newly Diagnosed Glioblastoma
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: Pro00054740, NCI-2015-00856, Amd005_Pro00054740, NCT02366728
SurVaxM Vaccine Therapy and Temozolomide in Treating Patients with Newly Diagnosed Glioblastoma
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: I 259614, NCI-2015-00694, NCT02455557
Basiliximab in Treating Patients with Newly Diagnosed Glioblastoma Multiforme Undergoing Targeted Immunotherapy and Temozolomide-Caused Lymphopenia
Phase: Phase I
Type: Diagnostic, Treatment
Age: 18 and over
Trial IDs: Pro00000581, NCI-2011-03848, CDR0000579683, SPORE Project 3, DUMC-PRO00000581, NCT00626483
Vaccine Therapy and Radiation Therapy in Treating Patients with Newly Diagnosed Glioblastoma
Phase: Phase I
Type: Treatment
Age: 18 and over
Trial IDs: 14-362, NCI-2014-02645, NCT02287428
A Study of DSP-7888 Dosing Emulsion in Adult Patients With Advanced Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: BBI-DSP7888-101, NCI-2015-01357, NCT02498665
HLA-A2-Restricted Synthetic Glioma Antigen Peptides Vaccine and MUC1 Peptide-Poly-ICLC Adjuvant Vaccine in Treating Patients With Brain Tumor
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: UPCI 07-057, NCI-2011-02465, CDR0000628889, R21CA133859-01A1, NCT00795457
Vaccine Therapy in Treating Patients With Recurrent Gliomas After Surgery
Phase: No phase specified
Type: Treatment
Age: 18 and over
Trial IDs: 08-135, NCI-2011-02491, NCT00874861
Imiquimod and Vaccine Therapy in Treating Younger Patients with Recurrent or Progressive Glioblastoma Multiforme or Diffuse Intrinsic Pontine Glioma
Phase: No phase specified
Type: Treatment
Age: 3 and over
Trial IDs: 2009LS136, NCI-2012-00322, NCT01400672
Vaccine Therapy and Imiquimod in Treating Patients With High Risk or Recurrent Grade II Gliomas
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: UPCI 11-136, NCI-2013-00078, NCT01678352
Vaccine Therapy and Temozolomide in Treating Patients With Newly Diagnosed Glioblastoma
Phase: No phase specified
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: MC1272, NCI-2013-01743, 13-000808, NCT01957956
Expanded Access Protocol for GBM Patients With Already Manufactured DCVax®-L Who Have Screen-Failed Protocol 020221
Phase: No phase specified
Type: Treatment
Age: 18 to 70
Trial IDs: 0202EA, NCI-2014-02473, NCT02146066
Start Over